Akums Drugs Q2 Net Profit Surges 168% on CDMO Business Growth
Akums Drugs and Pharmaceuticals reported a 168% year-on-year rise in consolidated net profit to around Rs 115 crore for Q2 FY27, driven by strong growth in its contract development and manufacturing organisation (CDMO) business. Revenue increased by about 30% to over Rs 1,340 crore, supported by higher API prices and improved operating margins. The CDMO segment, contributing over 80% of revenue, saw significant volume expansion and better capacity utilization. The company also noted sequential growth in revenue, EBITDA, and net profit, with ongoing investments to strengthen manufacturing capabilities.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 38/100.
Outlets measured: moneycontrol, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 2 Nov, 03:46 pm. Other outlets followed.
- 1